BizInt Smart Charts

What's New with the BizInt Smart Charts Family

ICIC, Berlin

15 October 2012

John Willmore, VP Product Development

Patents | Drug Pipelines | Clinical Trials | Sequences

- Improvements on STN, Orbit, Patbase, etc.
- Added support for Thomson Reuters **Cortellis**
- Generate links to **Thomson Innovation** and **Patentscope**
- Control over **publication number display**
- Many **new non-patent literature** files (STN)

- Continued improvements to ClinicalTrials.gov
- Improved mapping of fields between
  Citeline TrialTrove
  Adis Clinical Trials Insight
  ClinicalTrials.gov
- Generate Common Trial ID

- Added support for:
  DGENE and **PCTGEN** on STN
- Create a **standardized sequence ID**
  (e.g. from PSL or Note in DGENE)
- **Combine** results from **multiple queries**

- Improved **column selection**
- Easier **combine**/**update** operations
- New **Excel** and **Acrobat** exports
- **Move rows** command
- New toolbar, application **icons**

Challenges in multi-database reports

	Common Drug Name	Database	Status	Companies
1	FP-1039	Adis R&D Insight	Phase I	Five Prime Therapeutics (Originator) Human Genome Sciences (Licensee)
2	FP-1039	IMS R&D Focus		ePrime (USA) uman Genome Sciences (USA)
3	FP-1039	Thomson Pharma		ePrime Therapeutics Inc uman Genome Sciences Inc
4	FP-1039	Citeline Pipeline	Phase II	Five Prime Therapeutics Human Genome Sciences
5	lexatumumab	Thomson Pharma	Phase 2 Clinical	Cambridge Antibody Technology Group plc Human Genome Sciences Inc
6	lexatumumab	Adis R&D Insight	Discontinued I	Cambridge Antibody Technology (Originator) Human Genome Sciences (Licensee)
7	lexatumumab	Citeline Pipeline	No Development Reported	Human Genome Sciences AstraZeneca
8	lexatumumab	IMS R&D Focus	Phase I	Human Genome Sciences (USA)

1. Multiple Records for the Same Entity

Challenges in multi-database reports

	Common Drug Name	Database	Status	Companies
1	FP-1039	Adis R&D Insight	Phase I	Five Prime Therapeutics (Originator) Human Genome Sciences (Licensee)
2	FP-1039	IMS R&D Focus	Phase II	FivePrime (USA) Human Genome Sciences (USA)
3	FP-1039	Thomson Pharma	Phase 2 Clinical	FivePrime Therapeutics Inc Human Genome Sciences Inc
4	FP-1039	Citeline Pipeline	Phase II	Five Prime Therapeutics Human Genome Sciences
5	lexatumumab	Thomson Pharma	Phase 2 Clinical	Cambridge Antibody Technology Group plc Human Genome Sciences Inc
6	lexatumumab	Adis R&D Insight	Discontinued I	Cambridge A... tor) Human Geno...
7	lexatumumab	Citeline Pipeline	No Development Reported	Human Geno... AstraZeneca
8	lexatumumab	IMS R&D Focus	Phase I	Human Genome Sciences (USA)

2. Conflicting Data for the Same Entity

Challenges in multi-database reports

	Common Drug Name	Database	Status	Companies
1	FP-1039	Adis R&D Insight	Phase I	Five Prime Therapeutics (Originator) Human Genome Sciences (Licensee)
2	FP-1039	IMS R&D Focus	Phase II	FivePrime (USA) Human Genome Sciences (USA)
3	FP-1039	Thomson Pharma	Phase 2 Clinical	FivePrime Therapeutics Inc Huma
4	FP-1039	Citeline Pipeline	Phase II	Five Pr Huma
5	Iexatumumab	Thomson Pharma	Phase 2 Clinical	Cambridge Antibody Technology Group plc Human Genome Sciences Inc
6	Iexatumumab	Adis R&D Insight	Discontinued I	Cambridge Antibody Technology (Originator) Human Genome Sciences (Licensee)
7	Iexatumumab	Citeline Pipeline	No Development Reported	Human Genome Sciences AstraZeneca
8	Iexatumumab	IMS R&D Focus	Phase I	Human Genome Sciences (USA)

3. Terminology Variation

Challenges in multi-database reports

	Common Drug Name	Database	Status	
1	FP-1039	Adis R&D Insight	Phase I	Five Hum
2	FP-1039	IMS R&D Focus		vel Hum
3	FP-1039	Thomson Pharma		vePrime Therapeutics Inc ima
4	FP-1039	Citeline Pipeline	Phase II	Five Pr Huma
5	le		cal	Cambridge Antibody Technology Group plc Human Genome Sciences Inc
6	le		l	Cambridge A Human Genc tor)
7	le		ent Reported	Human Genc AstraZeneca
8	lexatumumab	IMS R&D Focus	Phase I	Human Genome Sciences (USA)

1. Multiple Records for the Same Entity

2. Conflicting Data for the Same Entity

3. Terminology Variation

the vantage point

BizInt Smart Charts Edition

BizInt Smart Charts

Reference Rows™

the vantage point

BizInt Smart Charts

Edition

- Customized version of **VantagePoint** designed for BizInt Smart Charts users.
- Provides tools for **normalization, cleanup, analysis and visualization.**
- Uses the XML Smart Data Exchange format.
- Sold separately ($3000 for first user)
- Contact us to arrange a trial!

Clean-up company names…

	# Records	# Instances	
1	69	69	Hun
2	54	54	Hun
3	49	49	Hun
4	42	42	Hun
5	14	14	Glax
6	12	12	Mec
7	10	10	Glax
8	10	10	Glax
9	9	9	Ave
10	8	8	Ast
11	5	5	Amg
12	5	5	Hun
13	4	4	Cam

	# Records	# Instances	Companies:
1	219	219	Human Genome Sciences
2	38	39	GlaxoSmithKline
3	14	14	MedImmune
4	9	9	AstraZeneca
5	9	9	Aventis Behring LLC
6	9	9	Transgene
7	8	8	Takeda
8	7	7	Amgen
9	7	7	Cambridge Antibody Technology
10	7	7	Pfizer
11	6	6	Novartis
12	5	5	Genentech
13	5	5	Teva

Normalize phase terminology…

	# Records	# Instances	Status
1	26	26	Discontinued
2	11	11	Discontinued I
3	3	3	Discontinued II
4	7	7	Discontinued Preclinical
5	1	1	Discontinued preregistra
6	5	5	overy
7	3	3	hed
8	2	2	Mar
9	62	62	No De me port
10	1	1	No develo reporte
11	16	16	No devel reporte
12	3	3	Phase nic
13	2	2	Ph Clinical
14	8	8	e I
15	10	10	ase II
16	6	6	Phase III
17	1	1	Pre-registration
18	40	40	Preclinical
19	2	2	Preregistration
20	3	3	Research
21	3	3	Suspended
22	1	1	Suspended II
23	4	4	Technology

	# Records	# Instances	Status (1)
1	79	79	No Development Reported
2	52	52	Discontinued
3	45	45	Preclinical
4	13	13	Phase 2
5	8	8	Phase 1
6	8	8	Phase 3
7	5	5	Launched
8	4	4	Technology
9	3	3	Biological Testing
10	3	3	Preregistration

BizInt Smart Charts

Reference Rows™

- Information from related records is displayed in a **single "Reference Row"…**
- …based on **database rankings and rules** that you define.
- A **separate utility** working with patent, drug pipeline, and clinical trial reports.
- Included in all BizInt Smart Charts licenses.

Now we can provide better tabular reports.

Human Genome Sciences - Pipeline (TP, RDI, RDF, CP - Aug 2012)

	Drug	Database	Status (Arabic)	Companies (Cleaned)	Update Date	Summary
1.	balugrastim	1.1 TPharm | link 1.2 IMS | link 1.3 PipeIn | link	Phase 3	Aventis Behring LLC CoGenesys Inc Human Genome Sciences Teva	2012-08-07	Teva Pharmaceutical Industries, following the acquisition of CoGenesys, under license from Human Genome Sciences (HGS, formerly Principia), and under license from Aventis Behring (now ZLB Behring), is developing balugrastim (CG-10639, Neugranin, Albugranin), a long-acting form of G-CSF created by fusion to albumin, for the potential treatment of chemotherapy-induced neutropenia [447883], [678434], [778202], [780827], [878888] [CONT.]
		1.1 TPharm			1.1 TPharm	1.1 TPharm
2.	Darapladib	2.1 Adis | link 2.2 Adis | link 2.3 IMS | link 2.4 PipeIn | link	Phase 3	GlaxoSmithKline Human Genome Sciences	2012-08-23	Darapladib (SB-480848) is an oral once-daily lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor isolated from Pseudomonas fluorescens, under development by GlaxoSmithKline (GSK) for the treatment of atherosclerosis and diabetic macular oedema (DMO) (Company pipeline, GSK, Feb 2001; USAN Web Page, 8 Nov 2005; Company presentation, GSK, 5 Feb 2009; Ann Rep, GSK, 2011, page 236, http://www. [CONT.]
		2.1 Adis			2.3 IMS	2.4 PipeIn
3.	FP-1039	3.1 TPharm | link 3.2 Adis | link 3.3 IMS | link 3.4 PipeIn | li	Phase 2	Five Prime Therapeutics Genome	2012-08-07	FivePrime Therapeutics and licensee Human Genome Sciences (HGS), a subsidiary of GlaxoSmithKline, are developing FP-1039 (HGS-1036), a soluble fusion protein comprising the extracellular domain of FGFR-1C linked to the Fc domain of IgG1 as a FGFR-1C antagonist that binds to several ligands that are key drivers of tumor growth, for the potential iv treatment of cancer such as breast, lung, ovarian and endometrial tumors [664645], [1108287], [1108288], [1162681], [1176971] [CONT.]
		3.1 TPharm			3.2 Adis	3.1 TPharm

Clean and clear!

Or graphs…



Accurate & useful!

Or network diagrams.



Accurate & intriguing!



BizInt Smart Charts

SINCE 1996

Come by our stand or go to:

www.bizcharts.com / tips